City Therapeutics, a clinical-stage biotech company focused on RNA interference (RNAi) therapies, priced its upsized initial public offering (IPO) at $18 per share, raising approximately $200 million before expenses. The company offered 11.1 million shares, with an option for underwriters to buy an additional 1.67 million shares. Proceeds will support development of its lead RNAi programs targeting thromboembolic diseases, retinal diseases, and anemia. Trading on Nasdaq under ticker CTY is expected to begin October 16, 2026, with closing anticipated on October 19, 2026.
City Therapeutics' IPO pricing is noted here with Pluang's Health sector market data as of Oct 16, 2026 10:01 WIB. Of 150 priced Health-sector US stocks tradable on Pluang, 129 rose and 20 fell today. Notable movers include COGT at USD 29.64 with a 1-day change of +5.29%, ALNY at USD 235.58 with +4.95%, and CGC at USD 0.75 with +4.94%, where CGC's Pluang order activity was 100% Sell / 0% Buy.
The FDA has approved Roche's Enspryng (satralizumab) as the first and only at-home subcutaneous treatment for adults with thyroid eye disease (TED). This approval follows positive results from Phase III SatraGO-2 trials showing significant reductions...
U.S. spot Ethereum ETFs experienced $60.22 million in net outflows on October 15, continuing a two-day streak of withdrawals. BlackRock's ETHA and Grayscale's ETHE led the outflows with $44.39 million and $18.28 million respectively, while Fidelity's...
Tesla has rapidly expanded its Cybercab robotaxi fleet in Austin, increasing the number of vehicles more than eight times within a month to over 300. This significant growth suggests Elon Musk's vision for autonomous robotaxis is gaining traction. Th...
Lavazza, operated by Yum China, has opened its fifth store in Hong Kong less than a year after its first, with plans to expand to around 10 stores soon. The brand is introducing its signature Buffalo Milk Latte, a popular drink in Mainland China made...
Emergent Metals Corp. has filed amended and restated financial statements for Q2 2026 to correct accounting and disclosure issues, affecting share capital and comprehensive loss figures but not net loss or assets. The company also provided an update ...
